Zogzas Charles E, Mukhopadhyay Somshuvra
Division of Pharmacology & Toxicology, College of Pharmacy; Institute for Cellular & Molecular Biology; and Institute for Neuroscience, The University of Texas at Austin, 3.510E BME, 107 W. Dean Keeton, Austin, TX, 78712, USA.
Adv Neurobiol. 2017;18:35-49. doi: 10.1007/978-3-319-60189-2_3.
While the neurotoxic effects of manganese were recognized in 1837, the first genetic disorder of manganese metabolism was described only in 2012 when homozygous mutations in SLC30A10 were reported to cause manganese-induced neurotoxicity. Two other genetic disorders of manganese metabolism have now been described - mutations in SLC39A14 cause manganese toxicity, while mutations in SLC39A8 cause manganese and zinc deficiency. Study of rare genetic disorders often provides unique insights into disease pathobiology, and the discoveries of these three inherited disorders of manganese metabolism are already transforming our understanding of manganese homeostasis, detoxification, and neurotoxicity. Here, we review the mechanisms by which mutations in SLC30A10, SLC39A14, and SLC39A8 impact manganese homeostasis to cause human disease.
虽然锰的神经毒性作用早在1837年就已被认识到,但直到2012年才首次描述了锰代谢的遗传性疾病,当时有报道称SLC30A10基因的纯合突变会导致锰诱导的神经毒性。现在又描述了另外两种锰代谢的遗传性疾病——SLC39A14基因的突变会导致锰中毒,而SLC39A8基因的突变会导致锰和锌缺乏。对罕见遗传性疾病的研究常常能为疾病的病理生物学提供独特的见解,这三种遗传性锰代谢疾病的发现已经改变了我们对锰稳态、解毒和神经毒性的理解。在此,我们综述了SLC30A10、SLC39A14和SLC39A8基因的突变影响锰稳态从而导致人类疾病的机制。